Abstract | BACKGROUND: METHODS: This is an open-label, multicenter, prospective, and randomized phase II controlled trial of 63 children with biopsy-proven proteinuric mild IgA nephropathy. We compared efficacy and safety between patients undergoing lisinopril monotherapy and patients undergoing combination therapy of lisinopril and losartan to determine better treatment for childhood proteinuric mild IgA nephropathy. RESULTS: There was no difference in proteinuria disappearance rate (primary endpoint) between the two groups (cumulative disappearance rate of proteinuria at 24 months: 89.3% vs 89% [combination vs monotherapy]). Moreover, there were no significant differences in side effects between the two groups. CONCLUSIONS: CLINICAL TRIAL REGISTRATION: Clinical trial registry, UMIN ID C000000006, https://www.umin.ac.jp .
|
Authors | Yuko Shima, Koichi Nakanishi, Mayumi Sako, Mari Saito-Oba, Yuko Hamasaki, Hiroshi Hataya, Masataka Honda, Koichi Kamei, Kenji Ishikura, Shuichi Ito, Hiroshi Kaito, Ryojiro Tanaka, Kandai Nozu, Hidefumi Nakamura, Yasuo Ohashi, Kazumoto Iijima, Norishige Yoshikawa, Japanese Study Group of Kidney Disease in Children (JSKDC) |
Journal | Pediatric nephrology (Berlin, Germany)
(Pediatr Nephrol)
Vol. 34
Issue 5
Pg. 837-846
(05 2019)
ISSN: 1432-198X [Electronic] Germany |
PMID | 30284023
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Drug Therapy, Combination
(adverse effects, methods)
- Female
- Glomerulonephritis, IGA
(complications, diagnosis, drug therapy, pathology)
- Humans
- Kidney Glomerulus
(pathology)
- Lisinopril
(administration & dosage, adverse effects)
- Losartan
(administration & dosage, adverse effects)
- Male
- Prospective Studies
- Proteinuria
(diagnosis, drug therapy, etiology, urine)
- Severity of Illness Index
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|